In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines how advances in cannabis-based pain research are accelerating mainstream acceptance of cannabis and its compounds. Citing peer-reviewed studies on terpenes matching or exceeding morphine’s effects in neuropathic pain models, along with growing evidence around CBD’s role in pain modulation and opioid-related harm reduction, the article frames pain management as a central driver of cultural, medical, and legislative change. Mazza connects emerging science, professional sports adoption, and shifting public opinion to argue that effective, non-addictive pain treatments may be the key catalyst for broader cannabis normalization.

In this guest column, Scott Mazza examines emerging peer-reviewed research supporting the cannabis “entourage effect,” arguing that cannabinoids, terpenes, and flavonoids interact synergistically to influence therapeutic outcomes beyond isolated compounds alone. Citing findings published in Molecules, the article explains how these interactions may shape analgesic, anti-inflammatory, and neuroprotective effects, while also highlighting the need for further research to clarify compound-specific contributions. Mazza situates these findings within a broader shift toward whole-plant and chemistry-driven approaches to cannabis formulation, treatment, and classification.

In a guest column for NY Cannabis Insider, Scott Mazza explains how the one-year extension of the 2018 Farm Bill delays long-awaited clarity on CBD regulation and hemp-derived cannabinoids, including delta-8 THC, prolonging uncertainty for producers, consumers, and regulators. He outlines how the extension constrains industry planning and innovation while urging producers to rely on third-party testing, transparent labeling, and compliance with existing hemp thresholds to protect consumers during the interim. Mazza argues that clearer federal definitions and enforceable standards in Farm Bill 2024 are essential to stabilize the market, address emerging cannabinoid loopholes, and align regulation with growing scientific evidence and public acceptance.

In a guest column for NY Cannabis Insider, Scott Mazza analyzes new toxicology research that establishes evidence-based upper limits for daily CBD intake, moving the industry beyond informal dosage “guesstimates.” He highlights findings indicating that healthy adults can safely consume up to 160 mg of CBD per day, while lower limits apply to pregnant or breastfeeding individuals and those at risk of liver injury. Mazza argues that clearly defined dosage thresholds are a necessary step toward responsible regulation, informed consumer use, and the integration of CBD into mainstream health and wellness frameworks.

In a guest column for NY Cannabis Insider, Scott Mazza reviews emerging clinical evidence linking cannabis-based therapies to symptom relief in fibromyalgia, a chronic condition affecting millions of Americans with limited treatment options. He cites recent studies showing that THC- and cannabinoid-containing formulations were associated with statistically significant improvements in pain, depression, and quality of life, as well as reduced reliance on conventional medications. Mazza emphasizes that realizing this therapeutic potential will require more rigorous research alongside stricter industry standards for cannabinoid product purity, potency, and consistency to support medical use.

In this guest analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines emerging clinical evidence on cannabidiol (CBD) as a sleep aid, contextualizing it against widespread sleep disorders in the U.S. He reviews a large peer-reviewed study showing that low doses of CBD can improve sleep quality with a favorable safety profile, performing comparably to melatonin, and without added benefit from minor cannabinoids. The article emphasizes both the promise and the limits of current evidence, underscoring the importance of product quality, third-party testing, and realistic expectations when considering CBD for sleep.

In this NY Cannabis Insider guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines Google’s 2023 policy shift allowing limited advertising for compliant, hemp-derived CBD products. He explains how certification requirements, age and geography restrictions, and third-party testing create new, but highly regulated, digital marketing pathways, while also reinforcing quality and consumer protection standards. Mazza positions the change as a meaningful step toward legitimizing the CBD industry and reshaping public perception through responsible, transparent advertising.

In this guest column, Scott Mazza of Vitality CBD examines emerging peer-reviewed research suggesting that cannabidiol may help reduce opioid reward, alleviate pain, and enhance the effectiveness of naloxone in overdose response. Mazza argues that these findings position CBD as a potentially valuable adjunct in addressing the opioid crisis, but only if products meet medical-grade standards for purity, potency, and consistency. The article stresses that meaningful clinical application will depend on stricter regulation, independent testing, and the elimination of low-quality products that currently undermine safety and credibility.

In this guest column, Scott Mazza of Vitality CBD explains how terpenes (the aromatic compounds in cannabis) contribute to distinct physiological effects and play a critical role alongside cannabinoids in the entourage effect. Citing a large-scale study analyzing thousands of real-world consumption sessions, Mazza highlights evidence that specific terpene profiles are associated with different outcomes for pain, anxiety, and depression. The article argues that moving beyond strain names toward chemistry-based classification could improve transparency, product selection, and medical credibility across both cannabis and CBD markets.

In this guest column, Scott Mazza of Vitality CBD outlines how emerging clinical research, particularly phase 2 data on anxiety and studies on menopause, signals a shift from anecdotal claims toward scientific validation of CBD. Mazza argues that regulatory inaction around CBD, Delta-8, and dietary supplement status continues to hinder industry legitimacy, calling for clearer federal oversight and enforcement against low-quality products. He also points to changing social attitudes, especially in sports and mainstream sponsorships, as evidence that CBD is entering a more mature and credible phase heading into 2023.

In this guest analysis, Scott Mazza, co-founder of Vitality CBD, examines emerging clinical evidence supporting CBD’s role in anxiety treatment, citing a Phase 2 trial showing significant symptom reduction with low-dose, full-spectrum CBD oil. Mazza highlights improvements in mood, sleep, and cognitive function, underscores the potential advantages of full-spectrum formulations over isolates, and calls for continued clinical research to establish standardized dosing and therapeutic guidance.

In this guest column, Scott Mazza of Vitality CBD examines emerging preclinical research on CBD’s potential role in alleviating menopause-related symptoms. Citing a first-of-its-kind study published in Frontiers in Pharmacology, Mazza explains how CBD influenced metabolism, inflammation, bone density, and gut health in estrogen-deficient models, while emphasizing the need for further human research, rigorous product standards, and third-party testing as interest in CBD-based menopause support continues to grow.